Droplet Digital PCR for Cancer and Liquid Biopsy Studies
 This presentation is no longer available.
 

Droplet Digital PCR for Cancer and Liquid Biopsy Studies
Thursday, November 7, 9:00 AM PST
Dawne Shelton PhD, Senior Scientist 

Droplet Digital PCR (ddPCRTM) is being used to identify cancer subtypes, optimize drug treatment plans, monitor residual disease, and study tumor evolution. ddPCR offers advantages in the field of liquid biopsies, enabling circulating nucleic acids (cfDNA) and circulating tumor cells (CTCs) to be measured in blood. ddPCR can detect rare tumorigenic mutations in a high background of "normal" DNA, routinely down to 0.01% and often further. We will discuss the technique and methods that will enable you to begin your own investigations.

Speaker Information: Dawne Shelton earned her PhD in oncological sciences from the University of Utah, Huntsman Cancer Institute. She has investigated different aspects of the Wnt pathway in colon cancer, studied the origins of the different subtypes of breast cancer, and examined uterine cancer in a clinical cancer research lab. She is now a senior scientist at the Digital Biology Center, focusing on developing applications and collaborations for ddPCR in the cancer field.


  Test Your System
 Help
  Download Flash Player